General Framework for Meta-Analysis of Haplotype Association Tests by Wang, Shuai et al.
General Framework for Meta-analysis of Haplotype
Association Tests
Shuai Wang1, Jing Hua Zhao2, Ping An3, Xiuqing Guo 4, Richard A. Jensen 5,16, Jonathan
Marten 6, Jennifer E. Huffman 6, Karina Meidtner 7, Heiner Boeing 8, Archie Campbell 9,
Kenneth M Rice15, Robert A Scott2, Jie Yao 4, Matthias B Schulze 7,10, Nicholas J Wareham2,
Ingrid B. Borecki3, Michael A. Province3, Jerome I. Rotter 4, Caroline Hayward 6 9, Mark O.
Goodarzi11, James B. Meigs 12 13, Jose´e Dupuis 1∗ 14,
1 Department of Biostatistics, Boston University School of Public Health, Boston, MA,
USA
2 MRC Epidemiology Unit, University of Cambridge, School of Clinical Medicine, Box
285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United
Kingdom
3 Department of Genetics Division of Statistical Genomics, Washington University School
of Medicine, St. Louis, Missouri, USA
4 The Institute for Translational Genomics and Population Sciences, Department of
Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance, California, USA
5 Cardiovascular Health Research Unit, University of Washington, Seattle, Washington,
USA
6 MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh,
United Kingdom
7 Department of Molecular Epidemiology, German Institute of Human Nutrition
Potsdam-Rehbruecke, Nuthetal, Germany
8 Department of Epidemiology, German Institute of Human Nutrition
Potsdam-Rehbruecke, Nuthetal, Germany
9 Generation Scotland, Centre for Genomic and Experimental Medicine, University of
Edinburgh Institute of Genetic and Molecular Medicine, Western General Hospital,
Crewe Road, Edinburgh EH4 2XU, United Kindom
10 German Center for Diabetes Research (DZD), Germany
11 Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center,
Los Angeles, CA, USA
12 Massachusetts General Hospital, General Medicine Division, Boston, Massachusetts
02114, USA
13 Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
14 National Heart, Lung, and Blood Institute (NHLBI) Framingham Heart Study,
Framingham, Massachusetts 01702, USA
15 Department of Biostatistics, University of Washington, Seattle, WA, USA
16 Department of Medicine, University of Washington, Seattle, Washington, USA
∗ Correspondence: Jose´e Dupuis, 801 Massachusetts Ave, 3rd Floor, Boston, MA 02118
(617)638-5880, dupuis@bu.edu
Abstract
For complex traits, most associated single nucleotide variants (SNV) discovered to date have a
small effect, and detection of association is only possible with large sample sizes. Because of
patient confidentiality concerns, it is often not possible to pool genetic data from multiple
cohorts, and meta-analysis has emerged as the method of choice to combine results from
multiple studies. Many meta-analysis methods are available for single SNV analyses. As new
approaches allow the capture of low frequency and rare genetic variation, it is of interest to
jointly consider multiple variants to improve power. However, for the analysis of haplotypes
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formed by multiple SNVs, meta-analysis remains a challenge, because different haplotypes may
be observed across studies. We propose a two-stage meta-analysis approach to combine
haplotype analysis results. In the first stage, each cohort estimate haplotype effect sizes in a
regression framework, accounting for relatedness among observations if appropriate. For the
second stage, we use a multivariate generalized least square meta-analysis approach to combine
haplotype effect estimates from multiple cohorts. Haplotype-specific association tests and a
global test of independence between haplotypes and traits are obtained within our framework.
We demonstrate through simulation studies that we control the type-I error rate, and our
approach is more powerful than inverse-variance-weighted meta-anaysis of single SNV analysis
when haplotype effects are present. We replicate a published haplotype association between
fasting glucose-associated locus (G6PC2) and fasting glucose in 7 studies from the Cohorts for
Heart and Aging Research in Genomic Epidemiology Consortium and we provide more precise
haplotype effect estimates.
keywords: meta-analysis, haplotype association tests, family samples, linear mixed effects
model
Introduction
In recent years, genome-wide association studies (GWAS) have identified multiple common
variants associated with disease and disease-related traits. In a typical GWAS, association
between a trait and genetic variants is tested one variant at-a-time, and variants with weak
association routinely fail to be detected, especially in small cohorts. Therefore, meta-analysis is
often used by large consortia to increase statistical power [Stram, 1996; Zeggini et al., 2008;
Scott et al., 2012; Dupuis et al., 2010] to detect variants with a moderate to weak association
with the trait of interest. Even with large meta-analysis, variants identified to date only explain a
small proportion of the total heritability. In order to identify the source of the unexplained
heritability, emerging approaches have attempted to account for multiple variants at once when
evaluating association with a trait. Such approaches include penalized regression methods [Wu
et al., 2009; Li et al., 2011], pathway analysis [Holden et al., 2008], gene-based tests such as
burden [Madsen and Browning, 2009] and SKAT [Wu et al., 2010], and haplotype analysis
[Schaid et al., 2002; Tregouet et al., 2004; Liu et al., 2008]. Power of these approaches can be
enhanced by increasing sample size or combining multiple studies. Methods for meta-analysis
of gene-based tests are well established and widely used [Hu et al., 2013; Liu et al., 2014], but
there are no widely-used methods for the meta-analysis of haplotype association tests.
In this article, we propose a meta-analysis approach to combine haplotype association results
from multiple studies. In the first step of our method, each study provides regression estimates
and covariance matrix of haplotype effects, with adjustment for familial correlation to
accommodate familial samples or cryptic relatedness. In our second step, cohort-specific
haplotype effect estimates are pooled using a multivariate generalized least square meta-analysis
approach. A global association test and evaluation of the effect of each haplotype can be
obtained within our framework. We perform a simulation study to evaluate our approach,
comparing results with more traditional meta-analysis of single-variant association tests and
gene-based tests. Finally, we replicate a published haplotype association between a fasting
glucose-associated locus (G6PC2) and fasting glucose in 7 studies from the Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE) Consortium and are able to provide
more precise haplotype effect estimates than the prior report involving haplotype estimates from
a single cohort [Mahajan et al., 2015]. Code implementing the novel approach, along with a
tutorial, is available at http://sites.bu.edu/fhspl/publications/metahaplo.
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Methods
Haplotype association test at cohort level
Our approach is based on Zaykin et al.’s haplotype analysis method [Zaykin et al., 2002] for
unrelated samples. We incorporate random effects to account for family structure, making the
approach applicable to both family-based cohorts or unrelated samples (or a mix of the two).
Assuming in a cohort a total of n subjects are sequenced in a region with q SNVs and as a result,
K haplotypes are observed. A general linear (mixed-effect) model can be written as:
Y = Xα+ β1h1 + ...+ βKhK + b + , (1)
where
Y is a n× 1 quantitative trait vector, X is a n× p matrix of covariates (without intercept)
including for example, age, sex and associated genetic principal components controlling for
potential population stratification, α is a p× 1 coefficient vector for the p covariates adjusted,
each n× 1 vector hm (m = 1, · · · ,K) is the expected haplotype dosage, b is a n× 1 random
effect vector to account for the relatedness within families, and  is a n× 1 vector of the random
error terms. When haplotypem of the j-th (j = 1, · · · , n) subject is observed, hmj , the j-th
entry in hm is either 0, 1 or 2, i.e. the number of copies of haplotypem the j-th subject carries.
Otherwise, expected haplotype dosages E[hmj |Gj] are inferred from Gj, the q × 1 genotype
vector of the j-th subject using statistical algorithms such as the Expectation-Maximization
(EM) algorithm [Dempster et al., 1977]. For the j-th subject, the sum of theK haplotype dosage∑m=K
m=1 hmj is always equal to 2. The n× 1 random effect vector b is assumed to follow a
normal distribution N(0, σ2aΦ), where σ
2
a is the additive variance and Φ is the relationship
matrix (with entries equal to twice the kinship coefficient for related pairs and 0 for unrelated
pairs) derived from pedigree structure or genome-wide information; in unrelated samples, the
matrix Φ reduces to I, the n× n identify matrix.. Finally, the vector of error terms  follows a
normal distribution N(0, σ2eI), where σ
2
e is the variance of the error term.
Let Xo = (X,h1, · · · ,hK) denote the overall design matrix of size n× (p+K), and
define the overall variance matrix as Ω = σ2aΦ +σ
2
eI. The parameters α and βk (k = 1, · · · ,K)
are estimated as (XTo Ωˆ
−1Xo)−1XTo Ωˆ
−1Y, where Ωˆ is evaluated at the maximum likelihood
estimates σˆ2a and σˆ2e which can be obtained using the lmekin function in R package coxme
[Therneau, 2012]. Then the estimated variance of the effect estimates is obtained from
(XTo Ωˆ
−1Xo)−1. It reduces to an ordinary linear regression when applied to unrelated samples.
Meta-Analysis
We assume a total of N cohorts participate in the meta-analysis and the i-th (i = 1, · · · , N )
cohort provides the estimates βˆi and the covariance matrix ˆvar(βˆi) of the haplotype effects for
Ki haplotypes, and a total ofK ′ haplotypes are observed in at least one cohort. We propose a
multivariate meta-analysis approach [Becker and Wu, 2007] based on generalized weighted least
squares to combine the lengthKi haplotype effect estimates from each cohort, denoted by βˆi
for studies i = 1, · · · , N , into a single effect estimate vector β˜ of lengthK ′. The generalized
weighted least square approach is formulated as:
βˆ =

βˆ1
...
βˆN
 = Wβ + e =

1 0 0
0 . . . 0
0 0 1
...
...
...
1 0 0
0 0 1

 β
1
...
βK
′
+ e, (2)
where
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βˆi (i = 1, · · · , N ) is theKi × 1 haplotype coefficient vector for cohort i;
βˆ is the stacked haplotype coefficient vector from βˆi (i = 1, · · · , N );
β is theK ′ × 1 coefficient vector of the haplotype effects;
W =
 W 1...
WN
 is a∑iKi ×K ′ design matrix stacked from the N cohorts, whereW i
(i = 1, · · · , N ) is aKi ×K ′ matrix, with zeros and one in each row indicating which haplotype
effect is observed by cohort i;
e is the error term which is assumed to have a multivariate normal distribution with a mean
of 0 and a covariance matrix of Σ =

var(βˆ1) · · · 0
... var( ˆβk)
...
0 · · · var(βˆN )
.
Note that in the meta-analysis stage, cohort haplotypes are reordered to match the order assigned
to theK ′ haplotypes observed in at least one cohort, and the design matrix W reflects this
re-ordering. Furthermore, because Σ is unknown, we substitute the sample estimate
Σˆ =

ˆvar(βˆ1) · · · 0
... ˆvar( ˆβk)
...
0 · · · ˆvar(βˆN )
, hence the weighted least square estimator of β is
β˜ = (W′Σˆ−1W)−1W′Σˆ−1βˆ and V = Var(β˜) = (W′Σˆ−1W)−1.
Hypothesis Testing
The global null hypothesis of no association of any haplotype with the trait is expressed as
H0 : β
1 = β2 = ... = βK
′
(3)
To construct a test statistic to test for haplotype association, we reparameterize it into the
equivalent null hypothesis, where β1 is chosen from commonly observed haplotypes:
H0 : γ =
 γ
1
...
γK
′−1
 =
 β
2 − β1
...
βK
′ − β1
 =
 0...
0
 (4)
The null hypothesis can be tested using a Wald test statistic of the form
χ2 = γˆT[V∗]−1γˆ. (5)
where γˆ is estimated from β˜ and V∗ is the covariance matrix of γˆ, with a dimension of
(K ′ − 1)× (K ′ − 1) and the jj′-th element having the form V ∗jj′ = Vjj′ − Vj1 − Vj′1 + V11.
Under the null hypothesis, the wald-test statistic follows a χ2
K′−1 distribution asymptotically.
Cohorts for Heart and Aging Research in Genetic Epidemiology Consor-
tium
The Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) consortium
comprises multiple studies with the common goal of identifying genes and loci associated with
cardiovascular-related traits. Seven CHARGE cohorts contributed to a meta-analysis evaluating
the association between genetic variants and fasting glucose in 25,305 non-diabetic participants
(Table 1). Fasting glucose levels in mmol/l were analyzed in participants free of type-2 diabetes.
Type-2 diabetes was defined by cohorts referring to at least one of the following criteria: a
physician diagnosis of type-2 diabetes, on the anti-diabetic treatment of type-2 diabetes, fasting
plasma glucose≥ 7mmol/l, random plasma glucose≥ 11.1mmol/l or hemoglobin A1C
≥ 6.5%. Study-specific sample exclusions were detailed in [Wessel et al., 2015].
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Table 1. CHARGE cohorts
Cohort Sample size
Generation Scotland: Scottish Family Health Study* (GS) 7678
Framingham Heart Study* (FHS) 6561
Cardiovascular Health Study (CHS) 3525
Family Heart Study* (FamHS) 3393
Multi-Ethnic Study of Atherosclerosis (MESA) 2507
FENLAND (FLD) 1341
European Prospective Investigation into Cancer and Nutrition, Potsdam (EPIC-Potsdam) 300
Total 25305
*: Family-based cohort
Genotypes were obtained from the Illumina HumanExome BeadChip [Grove et al., 2013], a
genotyping array containing 247,870 variants discovered through exome sequencing in ∼
12,000 individuals, in which ∼ 75% of the variants are low-frequency variants (MAF< 0.5%).
The main content of the chip comprises protein-altering variants (nonsynonymous coding,
splice-site and stop gain or loss codons) seen at least three times in a study and in at least two
studies providing information to the chip design. We selected 4 G6PC2 variants previously
studied for their haplotype association with fasting glucose [Mahajan et al., 2015].
Simulation Studies
To evaluate the validity and power of our approach, we perform a simulation study varying the
number of cohorts included in the meta-analysis (5 or 10), and the type of samples (unrelated,
family-based, mix of the two). We also vary the sample size from 100 up to 1600 subjects per
cohort. See Table 2 for a description of the various study designs investigated in type-I error rate
and power.
Simulated trait values are dependent on sex, age and haplotypes/genetic variants (power
evaluation only). Sex of mothers and fathers (founders) are fixed in a heterosexual marriage but
are randomly assigned to offspring, with equal probability. The age for unrelated individuals and
the first offspring in a family are generated from a uniform distribution over the range 30 to 50.
Additional offspring’s ages are set to be within 5 years of the first offspring with at least a one
year gap (no twins), using a uniform distribution. For family samples, the age of the mother is
restricted to be 20 to 45 years older than her offspring, and the father’s age to be within 5 years
of the mother’s age, with a restriction that the age be at least 20 years older than the older
offspring.
We select the known T2D associated genes G6PC2 (chromosome 2) (Table 3-4) and JAZF1
(chromosome 7) (Table 5-6) to generate the reference panel haplotypes (Tables 3 and 4). We use
the observed haplotypes and frequencies estimated by EM-algorithm from 6561 participants
from the Framingham Heart Study. For example, in JAZF1 no single haplotype has a frequency
greater than 25% (Table 6) and 8 haplotypes have frequency greater than 1%.
Genotypes are simulated by randomly assigning a pair of haplotypes to founders, and by
dropping randomly-selected haplotypes to offspring assuming no recombination within
haplotypes. Although phasing information is available in our simulation setting, we do not use
the phase information when implementing our approach because such information is not
typically available in real datasets. We use the EM algorithm to infer expected haplotype dosage
conditional on genotypes, via R package haplo.stats [Sinnwell and Schaid, 2013].
When estimating haplotype effects at the cohort-level, rare haplotypes (frequency< 0.1%)
are collapsed, to stabilize the computation and to avoid potential singularities due to high LD
among SNVs.
Type-I error rate
For evaluating the type-I error rate of our new approach, a trait unassociated with the haplotypes
is simulated using a multivariate normal distribution with mean µˆ = 0.02× age + 0.5× sex
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(sex is set to 1 for males and to 2 for females) and a covariance matrix σ2aΦ + σ
2
eI , with
σ2a = σ
2
e = 0.5. Age and sex explained about 10% and 5% of the trait variance, respectively,
resulting in a trait with moderate heritability (h2 = σ
2
a
V ar(Y ) ≈ 0.42).
Cohort-specific analyses are performed by first estimating haplotypes using the EM
algorithm implemented in the R package haplo.stats, followed by regression analysis using
haplotype dosages and covariates as independent variables. Cohort results are then
meta-analyzed using the novel approach previously described, and the global association test
p-values are recorded. Ten thousand simulations are performed to assess the type-I error rate in
all scenarios (Table 2).
Table 2. Study Designs for Type-I error evaluation
Study Design # cohort Sample Sizes Type-I error Type-I error
(G6PC2) (JAZF1)
1 5 250 NF2 (×5) 0.010 0.010
2 5 250 NFv (×5) 0.010 0.012
3 5 100 NF2, 175 NF2, 400 U, 700 U, 1000 U 0.013 0.010
4 5 100 NFv, 175 NFv, 400 U, 700 U, 1000 U 0.011 0.011
5 5 100 NFv, 175 NFv, 250 NFv, 325 NFv, 400 NFv 0.011 0.012
6 10 250 NF2 (×5); 1000 U (×5) 0.010 0.011
7 10 400 U, 700 U, 1000 U, 1300 U, 1600 U 0.008 0.012
8 5 100 NF2, 175 NF2, 250 NF2, 325 NF2, 400 NF2 0.012 0.011
9 5 250 NF2, 125 NF2 (×2), 375 NF2 (×2) 0.011 0.011
1000 U, 500 U (×2), 1500 U (×2)
10 10 250 NFv (×7), 1000 U (× 3) 0.012 0.011
NF2: Nuclear family with 2 offspring;
NFv: Nuclear family with the number of offspring randomly selected to be between 1 and 4
U: Unrelated subjects;
Table 3. G6PC2 variants
Name Chr MapInfo dbSNPID Minor Major FHS MAF
exm-rs560887 2 169763148 rs560887 A G 0.293
exm239664 2 169763262 rs138726309 T C 0.0036
exm239667 2 169764141 rs2232323 C A 0.0078
exm239672 2 169764176 rs492594 C G 0.4553
Table 4. G6PC2 haplotype frequencies
rs560887 rs138726309 rs2232323 rs492594 FHS Frequency
C C A C 0.46
T C A G 0.29
C C A G 0.24
T C C G 0.006
C T A C < 0.001
T C A C < 0.001
C T A G < 0.001
C C C G < 0.001
Power Evaluation
The power of our novel haplotype meta-analysis approach is evaluated in a total of 16 scenarios
(phenotype datasets) divided into 4 study designs (Study Design 1 to 4 from Table 2), with
varying haplotype or SNV effects. For each scenario, we first compute the meta-analysis
haplotype global test statistic, and then compare to meta-analysis of both single variant tests and
gene-based tests. For single variant tests, we compute the meta-analysis test statsitic using
inverse-variance-weighted method which has been shown to be the most powerful when the
effect size is constant across cohorts [Zhou et al., 2011]. We then select the SNP with the
minimum meta-analysis p-value pmin = min{1≤i≤K}pi (K = 4 for G6PC2;K = 5 for
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JAZF1) and adjust the meta-analysis p-value for multiple testing using a Bonferroni correction
for the effective number of independent variants [Gao et al., 2008]. We denote the result for the
best SNP in the single variant analysis by ”min P”. For gene-based tests, we choose SKAT and
Burden test with Wu weights and perform the analysis using R package seqMeta [Voorman et al.,
2014]. We use α = 0.001 to evaluate the power of all four approaches.
For each scenario, the phenotype is simulated using a multivariate normal distribution with
mean µˆ and a covariance matrix σ2aΦ + σ
2
eI , with σ
2
a = σ
2
e = 0.5, but unlike the type-I error
scenarios, the value of µˆ depends on genotypes/haplotypes in addition to the covariates of age
and sex. We investigate 4 genetic effect scenarios: one or two causal genetic variants
(gene-based scenarios), or one or two causal haplotypes. For the causal variant scenario,
µˆ = 0.02× age + 0.5× sex + bg1 × g1 + bg2 × g2 where gj (j = 1, 2) is a vector containing
the number of minor alleles (0, 1 or 2) carried by individuals in the sample, and bgj is the effect
of variant j, set to
√
R2
2MAFj(1−MAFj) whereMAFj is the minor allele frequency of variant j
and R2 = 0.01 is the proportion of variance explained by this specific variant (haplotype).
When only one causal variant is included in the model, bg2 = 0. For the causal haplotype
models, µˆ = 0.02× age + 0.5× sex + bh1 × h1 + bh2 × h2 where hj is a vector containing
the number of haplotypes j (0, 1 or 2) carried by individuals in the sample, and bhj is the effect
of haplotype j, set to
√
R2
h¯j(1−h¯j/2) where h¯j is mean haplotype dosage of haplotype j and
R2 = 0.01. When only one causal haplotype is included in the model, bh2 = 0. For the JAZF1
gene, we select two haplotypes, GTATA (the most frequent haplotype) and GCGCG (the third
most frequent haplotype), to have an effect on the phenotype while all other haplotypes have no
effect on the phenotype. For models with single variant effects, we select rs849134 and rs38523
to have non-zero effect on the trait while all other genetic variants have no effect. For the
G6PC2 gene, we select CCAC and TCAG, the two most frequent haplotypes to have an effect on
the phenotype. For models with single variant effects, we select rs560887 and rs2232323 to have
non-zero effect on the trait.
A thousand simulations with 5 independent cohorts are performed to compare the power of
our approach to the single variant method adjusted for multiple testing and gene-based methods.
Table 5. JAZF1 variants (chromosome 7)
Name Position dbSNPID Minor Major MAF
exm-rs10486567 27976563 rs10486567 A G 0.2415
exm2270592 28039797 rs38523 C T 0.3683
exm-rs864745 28180556 rs864745 G A 0.4965
exm-rs1635852 28189411 rs1635852 C T 0.4973
exm-rs849134 28196222 rs849134 G A 0.4917
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Figure 1. Power of the haplotype meta-analysis approach compared to gene-based methods and
single SNV meta-analysis (min P) adjusted for multiple testing in the G6PC2 region, evaluated at
α = 0.001 in four study designs. Description of the 4 study designs used in the simulation can be found
in Table 2 (Study Design 1-4). The labels on the x axes denote that when 1 (SNV) or 2 (2SNVs) are
influencing the phenotypes, or 1 (1HAP) or 2 (2HAPs) have an effect on the phenotypes.
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Figure 2. Power of the haplotype meta-analysis approach compared to gene-based methods and
single SNV meta-analysis (min P) adjusted for multiple testing in the JAZF1 region, evaluated at
α = 0.001 in four study designs. Description of the 4 study designs used in the simulation can be found
in Table 2 (Study Design 1-4). The labels on the x axes denote that when 1 (SNV) or 2 (2SNVs) are
influencing the phenotypes, or 1 (1HAP) or 2 (2HAPs) have an effect on the phenotypes.
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Table 6. JAZF1 haplotype frequencies
Haplotype rs10486567 rs38523 rs864745 rs1635852 rs849134 Frequency
1 G T A T A 0.2327
2 G T G C G 0.2295
3 G C G C G 0.1608
4 G C A T A 0.1295
5 A T A T A 0.0866
6 A T G C G 0.0793
7 A C A T A 0.0434
8 A C G C G 0.0259
9 A T G T A 0.0029
10 A T A C A 0.0029
11 A C A C A 0.0023
12 G T A C A 0.0019
13 G T G T A 0.0017
14 G C G T A 0.0005
Results
Meta-analysis of 4 coding variants on G6PC2 region
G6PC2 is a known locus to affect FG level. Among the 17 exonic variants on the exome chip, 15
are rare variants (MAF<1%) and 2 are common variants (rs560887 with MAF=25.4%;
rs492594 with MAF =43.7%). Previous GWAS have identified the A allele of rs560887, one of
the two common variants to be associated with lower FG level ([Bouatia-Naji et al., 2008]:
β = −0.07mmol/l, p = 6× 10−16; [Dupuis et al., 2010]: β = 0.075± 0.003mmol/l,
p = 8.5× 10−122). A recent large-scale exome-chip analysis indicated that these 15 rare
variants also had a joint effect on FG [Wessel et al., 2015]. Our approach is applied to study the
association between the haplotype structure of four coding variants rs560887, rs138726309,
rs2232323 and rs492594 and FG, using CHARGE exome-chip data. We perform a
meta-analysis of 7 studies comprising of 3 family-based and 4 population-based cohorts with up
to 25305 non-diabetic European participants, to better understand how the overall haplotype
structure as well as how the single haplotype affect FG level.
With a meta-analysis sample size of 25305, we have successfully replicated a previous reported
haplotype analysis of 4 coding variants on G6PC2 region [Mahajan et al., 2015], but with higher
precision (Table 7). Our effect size estimates are consistent with previously published estimates,
in terms of both direction and magnitude. However, prior results were based on a single
population-based cohort with 4442 participants. In contrast, our analysis is based on seven
cohorts with over 25000 participants. Consequently we are able to estimate haplotype effect
sizes with more precision, as reflected in the smaller standard errors. Among the 5 haplotypes
shared by all 7 studies, one copy of the most significant haplotype, TCAG, decreases FG levels
by 0.074 (95%CI: [0.063,0.085])mmol/l, on average; one copy of the second most significant
haplotype, CCAG, increases the average FG levels by 0.039 (95% confidence interval (CI):
[0.028,0.050])mmol/l; and one copy of the third most significant haplotype, TCCG, decreasing
FG levels by an average of 0.12 (95% CI: [0.065,0.18])mmol/l. Most haplotype effect estimates
reported in Mahajan et al.[Mahajan et al., 2015] fall within our 95 % CI, with the exception of
estimates for TCCG (Mahajan et al’s estimates = 0.205), which fall just outside our reported CI.
Simulations
Ten scenarios with increasing diversity in the study designs of the cohorts included in the
meta-analysis are simulated to evaluate type-I error rate of our approach. The type-1 error is
well controlled in all scenarios investigated (Table 1).
In the simulations to evaluate power, our approach is shown to be almost as powerful as the
single SNV approach when SNVs are influencing the trait, but much more powerful to detect
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Table 7. Single haplotype association test using 4SNVs on G6PC2 region
rs560887 rs138726309 rs2232323 rs492594 β (SE) P-value Frequency βM (SEM )∗
C C A C 0.4394
T C A G -0.073 (0.0055) 4.56× 10−41 0.2671 -0.065(0.011)
C C A G 0.039 (0.0056) 5.98× 10−12 0.2645 0.034(0.012)
T C C G -0.12 (0.029) 2.82× 10−5 0.0065 -0.205(0.057)
C T A C -0.022 (0.056) 0.70 0.0021 -0.202(0.077)
T C A C -0.031 (0.020) 0.12 0.0195 NA
The haplotypes are observed in all cohorts except that the last one is observed only in FHS, CHS, GS and FamHS.
∗: βM and SEM denote the estimates from the paper of Mahajan et al.
true haplotype effects. For example, in the family based design scenarios, our approach is 40%
more powerful than single SNV analyses when 2 haplotypes have non-zero effect on the
phenotypes (Figure 1, 2). A similar pattern is observed for designs with a mix of unrelated and
related samples. The gain in power is smaller when a single haplotype is influencing the trait,
but present for all scenarios evaluated. When compared to the gene-based tests, our approach is
uniformly more powerful in all scenarios across all study designs (Figure 3, 4) because of the
Wu (default) weighing scheme that downweights common variants.
Discussion
We proposed a general meta-analysis approach to combine the haplotype association results
from multiple cohorts. Our approach imposes no restrictions on the haplotypes observed across
cohorts. Instead, our approach can incorporate information from haplotypes observed in a single
cohort in addition to haplotypes observed in multiple cohorts. In the first stage of our approach,
haplotype association analysis is performed at the cohort-level. Information about the haplotype
structure, frequencies, effect estimates and covariance of effect estimates is collected, and
meta-analyzed in a second stage using a generalized weighted least square approach. The
association between a trait and any single or multiple haplotypes can be easily evaluated within
our framework.
We evaluated the type-I error rate in a variety of scenarios with different cohort designs that
included a mix of unrelated and family samples. Type-I error rate was controlled in all scenarios
investigated. We also compared the power of our approach with single variant tests corrected for
multiple testing (min P approach), and demonstrated that our approach had equivalent power
when variants, but not haplotypes, influenced the trait, but was more powerful in the presence of
true haplotype effects. Our haplotype approach also provided more evidence for association
compared to gene-based tests applied with the default weighting scheme, as exemplified in a
recent large-scale exome-chip project [Wessel et al., 2015] applied to the G6PC2 region
comprising 15 rare variants (MAF<1%). Our simulations also illustrated that the haplotype
effect size estimates obtained from meta-analysis were unbiased, even when family-based
cohorts were included.
While our approach can not serve as the only tool for the discovery of associated variants and
regions, it is a complementary tool to single-variant and gene-based tests. Mahajan et al.
[Mahajan et al., 2015] demonstrated the usefulness of haplotype analysis in their investigation of
the effect of G6PC2 variants on fasting glucose. In 4442 non-diabetic subjects from the Oxford
Biobank, the G allele from the coding variant rs492594 appears to significantly decrease fasting
glucose levels. However, when conditioning on the variant with largest effect (rs560887) on
fasting glucose, the effect estimates of the G-allele from rs492594 is reversed, and the G allele
appears to decrease fasting glucose, an apparent paradox. However, looking at the haplotype
estimates elucidates the mystery: the rs492594 G allele is most frequently observed on the same
haplotype as the glucose raising allele (T) from the strongest associated variant (rs560887),
giving the impression that the G allele also increases fasting glucose. Our analysis supports this
conclusion, and refines the effect estimates provided by Mahajan et al. by increasing the number
of samples used to obtain effect estimates via meta-analysis.
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Our approach has some limitations. The variants included in the haplotype analysis must be
genotyped or imputed in all cohorts. In other words, all cohorts must include the same set of
variants in their analysis. Moreover, when using imputed genotypes, best-guess genotypes must
be used because the approach does not currently handle genotypes in the form of dosage. The
EM algorithm currently employed for inferring haplotypes works best for a moderate number of
variants (< 15), and very rare haplotypes (frequency< 0.1%) cannot be evaluated and must be
collapsed to ensure computation stability. Despite these limitations, our approach has the
potential to shed some light on the relationship between traits and multiple associated SNVs in a
region.
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